Alfons Schwarz

Consultancy Services, Small Biotech, Study Start-Up and Execution Phase

Thalwil, Zurich, Switzerland

About

Alfons Schwarz Profile • More than 20 years of leadership experience in the pharmaceutical/biotech industry at Global Headquarter and Country level • Global and country level experience in clinical project and data management with CROs and Sponsors • Management of and collaboration on various projects in diverse therapeutic areas - Animal Health, Dermatology , Diabetes, Gastroenterology, Insomnia, Nephrology, Oncology, Ophthalmology, Orthopedic, Pediatrics, Rheumatology, NPC-C (Ultra Rare Disease) Summary of key strength • Excellent team player • Flexible and transparent with good analytical and organizational skills • Strong relationship builder and bridging global and country level teams • Committed and reliable to deliver high impact results with integrity • Ability to lead necessary changes and restructuring of operations and motivate high performing teams • General line management Professional Education: Various internal and external courses and seminars in: • Leadership • Effective logistic management • Personal presentation and self confidence • Early clinical development • Contracts in clinical trials • Further education in Data Management (SAS PHEEDIT program) • Statistics • Mediation and Conflict Management

Experience

  • Consultancy Services at Self-employed
    Nov 2021 - Present · 4 yrs 8 mos

  • Studienmanager für klinische Studien at Quercis Pharma
    Mar 2021 - Oct 2021 · 8 mos

  • Consultancy SwissPharmAudit Project Management at SwissPharmAudit GmbH
    Jan 2021 - Mar 2021 · 3 mos

  • National/International Biotech Experience in Early Phase and Rare Disease at Biotech
    Jan 2010 - Dec 2020 · 11 yrs

  • Mallinckrodt Pharmaceuticals (Zug)
    • Manifestations of NiemannPick Type C1 (NPC1) Disease
      Apr 2018 - Nov 2018 · 8 mos

      Mallinckrodt Pharmaceuticals/Sucampo AG, Zug Responsible for the European and United States Lead of 3 programs in Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS-270 (2- hydroxypropyl-β-cyclodextrin) in Subjects with Neurologic Manifestations of NiemannPick Type C1 (NPC1) Disease

    • Program Director in a rare disease program NiemanPick NPC
      Apr 2017 - Nov 2018 · 1 yr 8 mos